Clinical Trial Search

Primary: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16…

Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926

Primary: MAAT-G Feasibility Completion Rate — 10 Participants

Primary: Number of Participants With Biopsy-proven Acute Rejection — 1; 2 Participants

Primary: Data Review Committee (DRC) Adjudicated Overall Response at Day 42 — 28.7 Response rate percentage

Primary: Percentage of Participants Meeting the Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at Week 48 — 9.4; 19.1; 16.3; 5.5 Percentage of participants — p== 0.848

Primary: Pain Scores — 41.5; 29.8; 37.9; 47.4 units on a scale

Primary: Maximal and Average Expiratory Tidal Volume During Mask Ventilation — 25; 26.52; 21.96; 23.33 Milliliter

Primary: Clinical Cure — 7; 10; 23 Participants

Primary: Overall Comfort Averaged Over All Follow-up Visits — 91.72; 91.54 units on a scale

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Consumption of Opioids During the First 24 Hours After Surgery. — 46.2; 35.0 mg morphine equivalents per 24 hours

Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338

Primary: Number of Participants With Relapse to Alcohol 6 Months After Treatment — 3 Participants